Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Certuity LLC

Certuity LLC raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 66.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,498 shares of the pharmaceutical company’s stock after buying an additional 2,189 shares during the period. Certuity LLC’s holdings in Vertex Pharmaceuticals were worth $2,153,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Chesapeake Asset Management LLC raised its position in shares of Vertex Pharmaceuticals by 110.0% during the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 33 shares during the period. Colonial Trust Co SC boosted its position in shares of Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 38 shares during the period. Total Investment Management Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $33,000. Financial Network Wealth Advisors LLC increased its stake in Vertex Pharmaceuticals by 50.9% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 29 shares in the last quarter. Finally, Y.D. More Investments Ltd increased its stake in Vertex Pharmaceuticals by 345.0% in the 3rd quarter. Y.D. More Investments Ltd now owns 89 shares of the pharmaceutical company’s stock worth $35,000 after purchasing an additional 69 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Stifel Nicolaus upped their price objective on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a research note on Friday, February 13th. Royal Bank Of Canada cut their price target on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a report on Friday, February 13th. Sanford C. Bernstein restated an “outperform” rating and issued a $577.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Leerink Partners raised their price objective on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research note on Monday, December 29th. Finally, UBS Group lifted their price objective on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Twenty-three investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $553.36.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target to $600, signaling meaningful upside from current levels and adding institutional momentum. Oppenheimer Raises Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $600.00
• Positive Sentiment: Bank of America reiterated/issued a bullish view that the stock is positioned to rise, supporting demand from fundamental analysts. Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Bank of America Analyst Says
• Positive Sentiment: Citigroup likewise published a positive forecast for VRTX, adding to the cluster of buy-side endorsements. Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Citigroup Analyst Says
• Positive Sentiment: Morgan Stanley projected strong price appreciation, further cementing a consensus of elevated analyst expectations. Morgan Stanley Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock
• Positive Sentiment: Truist raised its price target to $525 and kept a buy rating, another near‑term upside signal from a major sell‑side shop. Benzinga
• Positive Sentiment: News reports show the stock recently spiked (up ~9–10%) on an analyst upgrade, indicating momentum-driven buying can be swift. Vertex Pharmaceuticals (NASDAQ:VRTX) Trading 9.9% Higher on Analyst Upgrade
• Positive Sentiment: Clinical catalyst: a Vertex drug reduced proteinuria in a Phase III IgA nephropathy trial — a meaningful development that could expand the pipeline and long‑term revenue potential. Vertex drug cuts proteinuria in Phase III IgA nephropathy trial
• Neutral Sentiment: Vertex presented at Barclays’ healthcare conference (transcript available) — useful for detail on pipeline timelines and management guidance but not an immediate price mover by itself. Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Coverage note: articles report a rising biotech weighting/focus in Nasdaq indexes, which can support longer‑term passive demand for VRTX but is not an immediate earnings catalyst. Vertex Pharmaceuticals (NASDAQ:VRTX) Biotech Focus Rises In Nasdaq Index
• Negative Sentiment: Despite the bullish notes, the stock has pulled back and printed a larger intraday decline than the market in recent sessions, reflecting profit‑taking and short‑term volatility. Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
• Negative Sentiment: Some commentary flagged that while price moves have been strong, recent earnings‑estimate revision trends may limit near‑term follow‑through. Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $478.13 on Friday. The firm has a 50 day simple moving average of $469.68 and a 200 day simple moving average of $437.20. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68. The stock has a market cap of $121.46 billion, a P/E ratio of 31.19, a P/E/G ratio of 2.10 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same quarter in the prior year, the company posted $3.98 EPS. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Mark E. Bunnage sold 2,021 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $930,529.03. Following the transaction, the executive vice president directly owned 12,914 shares of the company’s stock, valued at approximately $5,945,993.02. This represents a 13.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Duncan Mckechnie sold 4,910 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the sale, the executive vice president directly owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 91,156 shares of company stock worth $42,845,497 over the last 90 days. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.